Showing results 1 to 1 of 1
| Title | Author(s) | Issue Date | |
|---|---|---|---|
EDP-514, a potent pangenotypic class II hepatitis B virus core inhibitor, demonstrates significant HBV DNA and HBV RNA reductions in a phase 1b study in viremic, chronic hepatitis B patients. Poster Presentation (SAT393) Proceeding/Conference:The International Liver Congress 2022, 22-26 June 2022. Journal of Hepatology | 2022 |